Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.
Published May 22, 2013 · Recall initiated: January 31, 2013
Summary
FDA records drug Class I recall D-324-2013, published May 22, 2013 and initiated January 31, 2013. Recalling firm: Gilead Sciences, Inc.; Status: Terminated; Reported quantity: 3,181 vials; Lot: Lot #: B120217A, Exp 05/15 - US Distribution. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Gilead Sciences, Inc.
- Distributor
- Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork facility distributed to Germany/Austria, Italy and Spain.
- Lot
- Lot #: B120217A, Exp 05/15 - US Distribution
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAVeklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences,October 9, 2024
- FDAVeklury (remdesivir) for injection, 100 mg/vial, Single-Dose Vial, Rx only, Manufactured for: Gilead Sciences,January 5, 2022
- FDAEmtriva (emtricitabine) Oral Solution, 10 mg/mL, 170 mL bottles, Rx only, Manufactured for Gilead Sciences,November 5, 2014
- FDATruvada (200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablets, 30 count bottles, Rx only,October 15, 2014
- FDASuper Power capsules, Proprietary Blend 570 mg, packaged in 2-count capsules per blister pack, Distributed by:May 22, 2013
- FDAROCK-IT MAN capsules, male sexual stimulant, packaged in 1-count (UPC 8 53447 02003 8) and 2-count (UPC 8May 22, 2013
Questions about this recall
Was Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1. recalled?
Yes. FDA published recall D-324-2013 on May 22, 2013. Reported hazard: Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail